| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
4 companies
Michael R Hayden is Director at ABCL and has filed Form 4s across 4 companies. Michael R Hayden's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $23.7M at current prices.
Historically, Michael R Hayden's trades have earned a middling insider score of 59/100 across 7 rated trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +12.5%.
The biggest single holding is ABCL (~$16.7M) as Director. Net of sales, the ABCL filings show accumulation of 123,665 shares.
Michael R Hayden has 50 Form 4 filings on record from January 2015 to August 2026, across 4 companies: Director at AbCellera Biologics (ABCL), 2020–2026; Director at Ionis Pharmaceuticals (IONS), 2019–2026; Director at Xenon Pharmaceuticals (XENE), 2015–2021, and 1 more.
The 80 reported transactions were 31 option or other derivative awards, 31 option exercises, 11 open-market purchases and 5 gifts, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 9 purchases worth about $4.6M and 1 sale worth about $2.5M.
The largest open-market purchase was 73,665 shares of ABCL at an average $20.00 on December 15, 2020, about $1.5M.
The only open-market sale was 100,000 shares of ABCL at an average $25.50 on June 22, 2021, about $2.5M. Twelve months later ABCL was down 53%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 24, 2026 | ABCL Abcellera Biologics Inc. | Director | Buy | 53,613 | $10.64 | $570,442.32 | +4.1% | - | - | |
| Aug 12, 2026 | ABCL Abcellera Biologics Inc. | Director | Buy | 46,387 | $10.37 | $481,033.19 | +3.6% | - | - | |
| Jul 31, 2026 | IONS Ionis Pharmaceuticals, Inc. | Director | Buy | 20,000 | $52.94 | $1,058,700.00 | +500.0% | -14.3% | - | |
| May 1, 2025 | IONS Ionis Pharmaceuticals Inc | Director | Buy | 15,000 | $31.86 | $477,900.00 | +42.6% | +36.8% | - | |
| Dec 23, 2024 | IONS Ionis Pharmaceuticals Inc | Director | Buy | 5,000 | $36.22 | $181,078.75 | +16.5% | -7.3% | +122.6% | |
| Sep 22, 2023 | ABCL Abcellera Biologics Inc. | Director | Buy | 20,000 | $4.91 | $98,200.00 | +1.5% | +13.8% | -48.2% | |
| Aug 8, 2023 | ABCL Abcellera Biologics Inc. | Director | Buy | 30,000 | $5.90 | $177,000.00 | +2.4% | -24.0% | -55.3% | |
| Jun 22, 2021 | ABCL Abcellera Biologics Inc. | Director | Sell | 100,000 | $25.50 | $2,550,000.00 | -9.1% | -6.4% | -53.4% | |
| Dec 15, 2020 | ABCL Abcellera Biologics Inc. | Director | Buy | 73,665 | $20.00 | $1,473,300.00 | +165.2% | - | - | |
| Aug 14, 2017 | XENE Xenon Pharmaceuticals Inc. | Director | Buy | 15,000 | $2.75 | $41,247.00 | +10.3% | - | - |